CH EPL (R5)
0.1.0 - ci-build

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: 5204201

Generated Narrative: RegulatedAuthorization MA-5204201

identifier: http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber/5204201

subject: MedicinalProductDefinition: extension = Tablet and solvent for rectal suspension,Distale Form der Colitis ulcerosa bei ungenügendem Ansprechen auf oder Kontraindikation für Mesalazin.; identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MPID#CH-7601001346451-5204201; domain = Human; combinedPharmaceuticalDoseForm = Tablet and solvent for rectal suspension; indication = Leichte bis mittelschwere Colitis ulcerosa des Rectums sowie des Colon sigmoideum.; legalStatusOfSupply = Abgabe auf ärztliche oder tierärztliche Verschreibung (B); additionalMonitoringIndicator = No Warning; pediatricUseIndicator = Zugelassen für die Anwendung bei Kindern; classification = budesonide,NA BWS Art 12. Abs. 5 VAZV,Synthetika,Originalpräparat

type: Marketing Authorisation

region: Switzerland

status: zugelassen

statusDate: 1993-06-18

holder: Organization Tillotts Pharma AG

regulator: Organization SMC

Generated Narrative: Organization #holder-Tillotts-Pharma-AG

identifier: urn:oid:1.2.276.0.76/100005174, GLN/7601001346451

name: Tillotts Pharma AG

Generated Narrative: Organization #regulator-SMC

identifier: urn:oid:1.2.276.0.76/100010911, GLN/7601001398511

name: SMC